semaglutide phase 2 exposure levels in STEP 1, STEP and the 2 trial Semaglutide 7.2mg achieved 20.7% weight

The caloric deficit and nutritional gaps are the targets

keto for weight loss, both can produce results, but particularly in the short term

Features: High potency 2000 mg per serving

A Nature Medicine review published in January 2026 described GLP-1 medicines as "being prescribed to growing numbers of patients worldwide" for an expanding list of indications and noted that "new, more effective molecules with optimised pharmacokinetics produce greater weight loss and some may be more effective for various metabolic disorders, through incorporation of one or more additional peptide epitopes." The clinical pipeline includes 39 GLP-1 receptor agonist drugs in development across 34 companies, with only seven coming from the top 20 pharmaceutical firms